Follow The Short Interest: Time to Reconsider Cascadian Therapeutics Incorporated (NASDAQ:CASC) After Less Short Sellers?

November 28, 2016 - By Linda Rogers   ·   0 Comments

Follow The Short Interest: Time to Reconsider Cascadian Therapeutics Incorporated (NASDAQ:CASC) After Less Short Sellers?

The stock of Cascadian Therapeutics Incorporated (NASDAQ:CASC) registered a decrease of 4.99% in short interest. CASC’s total short interest was 4.67 million shares in November as published by FINRA. Its down 4.99% from 4.92 million shares, reported previously. With 373,900 shares average volume, it will take short sellers 13 days to cover their CASC’s short positions. The short interest to Cascadian Therapeutics Incorporated’s float is 5.82%. About 819,264 shares traded hands or 23.92% up from the average. Cascadian Therapeutics Inc (USA) (NASDAQ:CASC) has declined 24.44% since April 25, 2016 and is downtrending. It has underperformed by 30.46% the S&P500.

Cascadian Therapeutics, Inc., formerly Oncothyreon Inc., is a clinical-stage biopharmaceutical company. The company has a market cap of $131.41 million. The Firm focuses on the development of therapeutic products for the treatment of cancer. It currently has negative earnings. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor 2 inhibitor.

CASC Company Profile

Cascadian Therapeutics, Inc., formerly Oncothyreon Inc., incorporated on October 7, 2007, is a clinical-stage biopharmaceutical company. The Firm focuses on the development of therapeutic products for the treatment of cancer. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor. The Company’s ONT-10 is a therapeutic vaccine targeting the Mucin 1 peptide antigen (MUC1). The Firm is engaged in developing preclinical product candidates in oncology using its Checkpoint kinase 1 (Chk1) kinase inhibitor and protocell technology. The Firm completed the evaluation of approximately two dosing cohorts in its Phase Ib trial of ONT-10 in combination with the anti-CD27 T-cell agonist antibody varlilumab in collaboration with other company.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Linda Rogers


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>